Compound Mechanism of Action and Polypharmacology can be Elucidated by Large-Scale Perturbational Profile Analysis

Abstract

Drug Mechanism of Action (MoA) is often represented as a small repertoire of tissue-independent, high-affinity binding targets. Yet drug activity and polypharmacology are also manifested through a broad range of off-target and tissue-specific effector proteins. To address this dichotomy, we generated a compendium of drug perturbation profiles for >700 oncology drugs in cell lines representing high-fidelity models of 23 aggressive tumor subtypes, as well as an integrative framework for the proteome-wide assessment of drug-mediated, tissue-specific differential protein activity. Extending MoA and polypharmacology assessment via proteome-wide, multi-tissue analyses revealed novel polypharmacology, including for MAPK, PI3K, and folate pathways inhibitors--as supported by Western blots, thermal shift assays, and structural analysis--as well as functional inhibitors of challenging oncoprotein targets, including MYC, CTNNB1, CENPF and UHRF1. The dataset and associated computational framework might be extensible to additional compound libraries, supporting global, quantitative approaches to defining the mechanisms of action of many drugs.